---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-011443"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T07:55:12.387985+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Viking Therapeutics prices $250M public offering of 17.2M shares at $14.50

## Summary
- Gross proceeds ~$250M from 17.2M shares at $14.50; underwriters have 30-day option for 2.6M additional shares.
- Net proceeds to fund development programs VK2809, VK2735, VK0214 and for general R&D and working capital.
- Lead bookrunners: William Blair and Raymond James; co-managers: BTIG, Oppenheimer, H.C. Wainwright, Maxim, Roth, Laidlaw.
- Offering expected to close on April 3, 2023, subject to customary closing conditions.

## SEC filing metadata
- accession: 0000950170-23-011443
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017023011443/0000950170-23-011443-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017023011443/vktx-20230329.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-011443
- JSON: https://secwatch.observer/filing/0000950170-23-011443.json
- Plain text: https://secwatch.observer/filing/0000950170-23-011443.txt

## Key facts
- Material Agreements
  Viking Therapeutics, Inc. entered into Underwriting Agreement with William Blair & Company, L.L.C., as representative of the several underwriters valued at approximately $250.0 million (effective 2023-03-29).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: William Blair & Company, L.L.C., as representative of the several underwriters
  - Value: approximately $250.0 million
  - Effective: 2023-03-29
  source text: On March 29, 2023, Viking Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with William Blair & Company, L.L.C. (the “Representative”), as representative of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 17,242,000 shares of the Company’s common stock (“Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1607678/000095017023011443/0000950170-23-011443-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.